| abstract |
The inventors of the present invention found that bilirubin oxidized metabolites and Cortisol were significantly increased and immunoglobulin free kappa chains (κFLC) and immunoglobulin free lambda chains (λFLC) were significantly decreased in ARMS patients. Therefore, the present invention provides a biomarker for diagnosis of ARMS comprising a biomarker selected from the group consisting of bilirubin oxidative metabolite, cortisol, κFLC or a fragment thereof, and λFLC or a fragment thereof more than one. By detecting the amount of the biomarker for diagnosis of ARMS of the present invention in a biological sample, ARMS can be diagnosed quickly, easily and accurately. |